1. Anderson W. A case of angiokeratoma. Br J Dermat 1898; 1: 113-117.

2. Fabry J. Ein Beitrag zur Kenntnis der Purpura haemorrhagic a nodularis (Purpura papulosa haemorrhagica Hebrae). Arch Dermatol Syph 1898; 43: 187-200.

3. Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L. Enzymatic defect in Fabry´s disease. Ceramidetrihexosidase deficiency. N Engl J Med. 1976; 276: 1163-1167.

4. Kint JA. Fabry´s disease: alpha-galactosidase deficiency. Science 1970; 167: 1268-1269.

5. Ohnishi A, Dick PJ. Loss of small peripheral sensory neurons in Fabry disease: histologic and morphometric evaluation of cutaneous nerve, spinal ganglia, and posterior columns. Arch Neurol 1974; 31: 120-127.

6. Tabira T, Goto I, Kuroiwa Y, Kikuchi M. Neuropathological and biochemical studies in Fabry’s disease. Acta Neuropathol 1974; 30: 345-354.

7. deVeber GA, Schwarting GA, Kolodny EH, Kowall NW. Fabry disease: immunocytochemical characterization of neuronal involvement. Ann Neurol 1992; 31: 409-415.

8. Desnick RJ, Ioannou YA, Eng CM. a-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic bases of Inherited Disease. 8th ed. New York: MacGraw-Hill; 2001: 3733-3774.

9. Meikle PJ, et al. Prevalence of lysosomal disorders. JAMA 1999; 28: 1249-1254.

10. Chamoles NA, Blanco M, Gagilo D. Fabry disease: enzymatic diagnosis in dried blood   spots on filter paper. Clin Chim Acta. 2001; 308: 195-196.

11. Schiffmann R, Kopp JB, Austin HA 3rd, Sabnis S, Moore DF, Weibel T, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001; 285: 2743-2749.

12. Eng CM, Gurron N, Wilcox WR, Germain DP, Lee P, Waldek S, et al. Safety and efficacy of recombinant human a-galactosidase A-replacement therapy in Fabry´s disease. N Engl J Med. 2001; 345:9-16.

13. Schiffmann R, Scott LJC. Pathophisiology and assessment of neuropathic pain in Fabry disease. Acta Paediatr Suppl 2002; 439: 48-52.

14. MacDermot KD, Holmes A,  Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 2001; 38: 769-775.

15. Kolodny EH, Pastores GM. Anderson-Fabry disease: Extrarenal, Neurologic Manifestations. J Am Soc Nephrol 2002; 13: 150-153.

16. Chowdhury MM, Holt PJ. Pain in Anderson-Fabry disease. Lancet 2001; 357: 887.

17. MacDermot J, MacDermot KD. Neuropathic pain in Anderson-Fabry disease: pathology and therapeutic options. Eur J Pharmacol 2001; 429: 121-125.

18. Birklein F. Mechanisms of neurophatic pain and their importance in Fabry disease. Acta Paediatr Suppl 2002; 439: 34-37.

19. Lettieri, C, Inglese C, Preda P, Alfieri S,  Gemignani F, Marbini A. Small fiber neuropathy in an 11-year-old boy with fabry disease. J Perip Ner Sys 2003; 8: 53-54. 

20. Woolf C, Mannion R. Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet 1999; 353: 1959-1964.

21. International Association for the Study of Pain. Classification of Chonic Pain. 2° ed. IASP Task Force on Taxonomy; Meskey H, Bogduk N. IASP Press. 1994

22. Devor M. The pathophysiology of damaged peripheral nerves. In: Wall PD, Meizack R, eds. Textbook of pain. Edinburgh: Churchill Livingstone, 1994: 79-100.

23. McLachlan EM,, Janig W, Devor M, Michaelis M. Peripheral nerve injury triggers noradrenergic sprouting within dorsal root ganglia. Nature 1993; 363: 543-546.

24. Torebjörk E, Wahren LK, Wallin G, Hallin R, Koltzenburg M. Noradrenaline-evoke pain in neuralgia. Pain 199; 63: 11-20.

25. Woolf JC. Evidence for a central component of post-injuty pain hypersensitivity. Nature 1983; 306: 686-688.

26. Woolf JC, Shortland P, Coggeshall RE. Peripheral nerve injury triggers central sprouting or myelinated afferents. Nature 1992; 355: 75-8.

27. Le-Bars D, Dickenson AH, Besson JM. Diffuse noxious inhibitory controls (DNIC): Efects on dorsal horn convergent beurones in the rat. Pain 1979; 6: 283-304.

28. Carriedo SG, Yin HZ, Sensi SL, Weiss JH. Rapid Ca2+ entry  through  Ca2+-permeable AMPA/Kainate channels triggers marked intracellular Ca2+ rises and consequent oxygen radical production. J Neurosci 1998; 18: 7727-38.

29. Lockman LA, Hunninghake DB, Krivit W, Desnick RJ. Relief of pain of Fabry´s disease by diphenylhydantoin. Neurology 1973; 23: 871-875.

30. Filling-Katz MR, Merrick HF, Finf JC, Miles RB, Sokol J, Barton NW. Carbamacepine in Fabry’s disease: effective analgesia with dose-dependent exacerbation of autonomic dysfunction. Neurology 1989; 39: 598-600.

31. Inagi M, Ohno K, Hisatorne I, Tanaka Y, Takeshita F. Relative hypoxia of the extremities in Fabry disease. Brain Dev. 1992; 14: 328-33.

32. Smith SA, Smith SE. Bilateral Horner’s syndrome: detection and occurrence. J Neurol Neurosurg Psychiatry 1999; 66 : 48-51.

33. Cable WJ, Kolodny EH, Adams RD. Fabry disease: impaired autonomic function. Neurology 1982; 32: 498-502.

34. Lao LM, Kumakiri M, Mima H, Kuwahara H, Ishida H, Ishiguro K, et al. The ultrastructural characteristics of eccrine sweat glands in a Fabry disease patient with hypohidrosis. J Dermatol. Sci. 1998; 18: 109-117.

35. Toyooka K, Said G. Nerve biopsy findings in hemizygous and heterozigous patients with Fabry’s disease. K Neurol 1997;  244: 464-8.

36. Sima AAF, Robertson DM. Involvement of peripheral nerve and muscle in Fabry’s disease. Histologic, ultrastructural and morphometric studies. Arch Neurol 1978; 35: 291-301.

37. Vital A, Vital C, Maleville J. Fabry’s disease: an ultrastructural study of muscle and peripheral nerve. Clin Neuropathol 1984; 3: 168-172.

38. Drachenberg CB, Schweitzer EJ, Bartlett ST, Behrens MT, Papadimitriou JC. Polyarteritis nodosa-like necrotizing vasculitis in Fabry disease. J Inherit Metab Dis 1993; 16: 901-902.

39. Okano H, Shiraki K, Tsuneoka K, Tamai T, Nakazawa S, Masuoka H, et al. Esophageal vascular ectasia associated with Fabry’s disease. Gastrointest Endosc 2001; 53: 125-126.

40. Field DG, Ostrov BE, Devenyi AG, Hoban TF. Achalasia in an adolescent with Fabry disease. J Paeditr Gastroenterol Nutr 2001; 32: 201-203.

41. Argoff CE, Barton NW, Brady RO, Ziesmann HA. Gastrointestinal symptoms and delayed gastric emptying in Fabry’s disease: Response to metoclopramide. Nucl Med Commun 1998; 19: 887-891.

42. Gadoth N, Sandbank U. Involvement of dorsal root ganglia in Fabry’s disease. J Med Genet 1983; 20: 309-312.

43. Hilz JM, Stemper B, Kolodny EH. Lower limb cold exposure induce pain and small fiber dysfunction in Fabry patients. Pain 2000; 84: 361-365.

44. Luciano CA, Russell JW, Banerjee TK, Quirk JM, Scott LJC, Dambrosia JM, et al. Physiological characterization of neuropathy in Fabry’s disease. Muscle Nerve 2002; 26: 622-629.

45. Syed NA, Sandbrink F, Luciano CA, Altarescu G, Weibel T, Schiffmann R, et al. Cutaneous silent periods in patients with fabry disease. Muscle Nerve 2000; 23: 1179-1186.

46. Ro LS, Chen ST, Tang LM, Hsu WCh, Chang HSh, Huang Ch. Current perception threshold testing in  fabry’s disease. Muscle Nerve 1999; 22: 1531-1537.

47. Hilz MJ. Evaluation of peripheral and autonomic nerve function in Fabry disease. Acta Paediatr Suppl 2002; 439: 38-42.

48. Dütsch M, Marthol H, Stemper B, Brys M, Haendl T, Hilz JM. Small fiber dysfunction predominates in Fabry neuropathy. J Clin Neuroph 2002; 19: 575-586.

49. Gomez I, Nora DB, Becker J, Ehlers JAC, Schwartz IVD, Giugliani R, et al. Nerve conduction studies, electromyography and sympathetic skin response in Fabry’s disease. J Neurol Scien 2003; 214: 21-25.

50. Scott LJC, Griffin JW, Luciano C, Barton NW, Banerjee T, Crawford JC, et al. Quantitative analysis of epidermal innervation in Fabry disease. Neurology 1999; 52: 1249-1254.

51. Cleeland CS. Pain assessment: the adventages of using pain scales in lysosomal storage diseases. Acta Paediatr Suppl 2002; 439: 43-47.

52. Melzack J. The short-form McGill Pain Questionnarie. Pain 1987; 30: 191-197.

53. Ries M, Mengel E, Kutschke G, Kim KS, Birklein F, Krummenauer, F, et al. Use of gabapentin to reduce chronic neuropathic pain in Fabry disease. J Inherit Metab Dis 2003; 26: 413-414.

54. Gordon KE, Ludman MD, Finley GA. Succesful treatment of painful crises of Fabry disease with low dose morphine. Paediatr Neurol 1995; 12: 250-251.

55. Inagaki M, Ohno K, Ohta S, Sakaruba H, Takeshita K. Relief of chronic burning pain in Fabry disease with neurotropin. Paediatr Neurol 1990; 6: 211-213.

56. Braine HG, Pyeritz RE, Folstein MF, Moser HB, Ullman MD. A prospective double-blind study of plasma exchange therapy for the acroparesthesia of Fabry’s disease. Tranfusion 1981; 21: 686-689.

57. Schiffmann R, Floeter MK, Dambrosia JM, Gupta S, Moore F, Sharabi Y, et al. Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve 2003 Artículo En Prensa.

58. Desnick R, Brady R, Barranger J, Collins A, Germain D, Goldman M, et al. Fabry disease, an under-recognized multysistemic disorder: expert recommendations for diagnosis, managment and enzyme replacement therapy. Ann Intern Med. 2003; 138: 338-346.

59. Ohsugi K, Kobayashi K, Itoh K, Sakuraba H, Sakuragawa N. Enzymatic corrections for cells derived from Fabry disease patients by a recombinant adenovirus vector. J Hum Genet 2000; 4: 1-5.
      
60. Ziegler RJ, Yew NS, Li C, Cherry M, Berthelette P, Romanczuk H, et al. Correction  of enzymatic and lysosomal storage. Defects in Fabry mice by adenovirus-mediated gene transfer. Hum Gene Ther 199; 10: 1667-1682.

61. Takiyama N, Dunigan JT, Vallor MJ, Kase R, Sakuraba H, Barranger JA. Retrovirus mediated transfer  of human a-galactosidase A gene to human CD34+ hematopoietic progenitor cells. Hum Gene Ther 1999; 10: 2881-2889.

62. Platt FM, Butters TD. New  therapeutic prospects for the Glycosphingolipid lysosomal storage disease. Biochem Pharmacol 1998; 56: 421-430.